Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J. Kudo M, et al. Among authors: aizawa m. Liver Cancer. 2021 Jun;10(3):249-259. doi: 10.1159/000514420. Epub 2021 Apr 7. Liver Cancer. 2021. PMID: 34239811 Free PMC article.
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
Tomita Y, Motzer RJ, Choueiri TK, Rini BI, Miyake H, Oya M, Albiges L, Aizawa M, Umeyama Y, Wang J, di Pietro A, Schmidinger M. Tomita Y, et al. Among authors: aizawa m. ESMO Open. 2023 Dec;8(6):102034. doi: 10.1016/j.esmoop.2023.102034. Epub 2023 Oct 20. ESMO Open. 2023. PMID: 37866029 Free PMC article.
Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H. Kato T, et al. Among authors: aizawa m. Int J Urol. 2024 Mar;31(3):265-272. doi: 10.1111/iju.15345. Epub 2023 Dec 18. Int J Urol. 2024. PMID: 38110838
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
Ono T, Hino M, Matsumura I, Fujisawa S, Ishizawa K, Sakaida E, Sekiguchi N, Ono C, Aizawa M, Tanetsugu Y, Koide Y, Takahashi N. Ono T, et al. Among authors: aizawa m. Int J Hematol. 2022 Dec;116(6):871-882. doi: 10.1007/s12185-022-03435-4. Epub 2022 Aug 13. Int J Hematol. 2022. PMID: 35963986 Free PMC article. Clinical Trial.
ASO Author Reflections: Preoperative Chemotherapy Provides Survival Benefits Compared with Upfront Surgery for Patients with Liver-Limited Metastasis from Gastric Cancer.
Hirose Y, Aizawa M, Yabusaki H, Nomura T, Takano K, Kawasaki T, Watanabe G, Shimojima Y, Yuza K, Bamba T, Nakagawa S. Hirose Y, et al. Among authors: aizawa m. Ann Surg Oncol. 2024 Jun;31(6):4052-4053. doi: 10.1245/s10434-024-15270-4. Epub 2024 Apr 9. Ann Surg Oncol. 2024. PMID: 38594577 No abstract available.
Material Design of Porous Hydroxyapatite Ceramics via Inverse Analysis of an Estimation Model for Bone-Forming Ability Based on Machine Learning and Experimental Validation of Biological Hard Tissue Responses.
Horikawa S, Suzuki K, Motojima K, Nakano K, Nagaya M, Nagashima H, Kaneko H, Aizawa M. Horikawa S, et al. Among authors: aizawa m. Materials (Basel). 2024 Jan 25;17(3):571. doi: 10.3390/ma17030571. Materials (Basel). 2024. PMID: 38591397 Free PMC article.
623 results